Will public-private partnerships take the leap into open science?

Pierre Meulien, Executive Director of the Innovative Medicines Initiative (IMI)
IMI – Europe’s partnership for health

IMI1: 2008-2013
€2 bn ($2.4 bn)
59 projects

IMI2: 2014-2020
€3.3 bn ($4 bn)
More ambitious
More open
Greater scope

Partnership 2008 - 2020

€2.5 bn

> €5 bn ($6 bn)
IMI – Europe’s partnership for health

IMI2 Strategic Research Agenda

- Antimicrobial resistance
- Osteoarthritis
- Cardiovascular diseases
- Diabetes
- Neurodegenerative diseases
- Psychiatric diseases
- Respiratory diseases
- Immune-mediated diseases
- Ageing-associated diseases
- Cancer
- Rare/Orphan Diseases
- Vaccines

Aligned with WHO priorities

Over 11 500 researchers from an international, cross-sector community

- SMEs 198
- Patient Groups 29
- Universities/academic organisations 530
- EFPIA members 43
- EFPIA Partners in Research 14
- Regulators 26
- Associated Partners 6
Open Innovation vs. Open Science

Open Innovation

- Model of collaboration
  “... combines internal and external ideas into architectures and systems whose requirements are defined by a business model ...”
  
  Chesbrough (2003)

- Inherent to IMI

Open Science

- Practice of science to remove barriers for sharing and accessing knowledge, data, etc.

- Also an EU political objective translated into EU policy
Making Open Science a Reality

Several components which may be independent from each other:

- Open Access to Research Data
- Open Access to Publications
- Open Source Software
- FAIR data stewardship
Our Panelists

• Carlo Incerti
  Head of Global Medical Affairs, Sanofi Genzyme

• David Wholley
  Senior Vice-President, Research Partnerships, Foundation for the National Institutes of Health

• Shyam Bishen
  US Regional Director, Life Sciences Partnerships Global Health, Bill and Melinda Gates Foundation

• Nikolay Savchuk
  Managing Director, Torrey Pines Investment